Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Co-activation: its association with weakness and specific neurological pathology | Journal of NeuroEngineering and Rehabilitation Research Co-activation its association with weakness and specific neurological pathology Monica E Busse 1 Charles M Wiles2 and Robert WM van Deursen1 BioMed Central Open Access Address Department of Physiotherapy Cardiff University Cardiff UK and 2Department of Neurology Cardiff University Cardiff UK Email Monica E Busse - busseme@ Charles M Wiles - wiles@ Robert WM van Deursen - vandeursenr@ Corresponding author Published 20 November 2006 Received 05 June 2006 _ A AAAZ 1AZ Accepted 20 November 2006 Journal of NeuroEngineering and Rehabilitation 2006 3 26 doi 1743-0003-3-26 This article is available from http content 3 1 26 2006 Busse et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Net agonist muscle strength is in part determined by the degree of antagonist coactivation. The level of co-activation might vary in different neurological disorders causing weakness or might vary with agonist strength. Aim This study investigated whether antagonist co-activation changed a with the degree of muscle weakness and b with the nature of the neurological lesion causing weakness. Methods Measures of isometric quadriceps and hamstrings strength were obtained. Antagonist hamstring co-activation during knee extension was calculated as a ratio of hamstrings over quadriceps activity both during an isometric and during a functional sit to stand STS task using kinematics in groups of patients with extrapyramidal n 15 upper motor neuron UMN n 12 lower motor neuron LMN with n 18 or without n 12 sensory loss primary muscle or neuromuscular junction disorder n 17 and in .
